Literature DB >> 16310411

Triggering TLR signaling in vaccination.

David van Duin1, Ruslan Medzhitov, Albert C Shaw.   

Abstract

Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as well as experimental, vaccines incorporate ligands for TLRs, not only to protect against infectious diseases but also in therapeutic immunization against noninfectious diseases, such as cancer. We review the underlying mechanisms by which engagement of TLR signaling pathways might trigger an adaptive immune response after immunization. Although the engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses, questions of efficacy, feasibility and safety remain the subject of active investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310411     DOI: 10.1016/j.it.2005.11.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  120 in total

Review 1.  Once a killer, always a killer: from cytotoxic T cell to memory cell.

Authors:  Leo Lefrançois; Joshua J Obar
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

3.  TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

Authors:  D M Appledorn; S Patial; S Godbehere; N Parameswaran; A Amalfitano
Journal:  J Innate Immun       Date:  2009-03-04       Impact factor: 7.349

Review 4.  Dysregulation of human Toll-like receptor function in aging.

Authors:  Albert C Shaw; Alexander Panda; Samit R Joshi; Feng Qian; Heather G Allore; Ruth R Montgomery
Journal:  Ageing Res Rev       Date:  2010-11-10       Impact factor: 10.895

5.  Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.

Authors:  Xinqiang Hong; Tiangen Dong; Jianwei Hu; Tuo Yi; Wenxiang Li; Zhen Zhang; Shengli Lin; Weixin Niu
Journal:  Int J Colorectal Dis       Date:  2012-07-10       Impact factor: 2.571

6.  The genetic background influences the cellular and humoral immune responses to vaccines.

Authors:  M Zeng; E Nourishirazi; E Guinet; M Nouri-Shirazi
Journal:  Clin Exp Immunol       Date:  2016-08-16       Impact factor: 4.330

7.  Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.

Authors:  Meini Wu; Haixuan Wang; Jiandong Shi; Jing Sun; Zhiqing Duan; Yanhan Li; Jianfang Li; Ningzhu Hu; Yiju Wei; Yang Chen; Yunzhang Hu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

9.  Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.

Authors:  Sylvia Adams; David W O'Neill; Daisuke Nonaka; Elizabeth Hardin; Luis Chiriboga; Kimberly Siu; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Erika Ritter; Rose Marie Holman; Richard L Shapiro; Russell S Berman; Natalie Berner; Yongzhao Shao; Olivier Manches; Linda Pan; Ralph R Venhaus; Eric W Hoffman; Achim Jungbluth; Sacha Gnjatic; Lloyd Old; Anna C Pavlick; Nina Bhardwaj
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.